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Abstract
Background: Peanut allergy is the most prevalent and dan-
gerous food allergy. Peanuts consist of a large number of dif-
ferent allergens and peanut-allergic patients are frequently 
sensitized to multiple allergens. Hence, conventional desen-
sitization approaches aim at targeting as many allergens as 
possible. Methods: The monoclonal anti-Ara h 2 antibody 
(mAb) was produced by hybridoma cells derived from WT 
BALB/c mice after immunization with a vaccine based on vi-
rus-like particles coupled to Ara h 2. BALB/c mice were sensi-
tized intraperitoneally with peanut extract absorbed to alum 
and mAbs were applied i.v. Challenge was performed the 
next day with the whole peanut extract intravenously and via 
skin prick test. Results: Here we show in peanut-allergic mice 
that a single high-affinity mAb specific for Ara h 2 is able to 
block systemic and local allergic reactions induced by the 
complex peanut extract. We confirm in vitro binding of the 
mAb to the inhibitory low-affinity FcγRIIb receptor using a 
sensitive biosensor and demonstrate in vivo that protection 
was dependent on FcγRIIb. Conclusion: A single mAb spe-
cific for Ara h 2 is able to improve local and systemic allergic 
symptoms induced by the whole allergen mixture.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Peanut allergy is a frequent disease in Western coun-
tries with an increasing prevalence currently ranging 
between 1.4 and 3% in children [1]. The disease typi-
cally develops early in life and is rarely outgrown with 
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age [2]. Peanut allergy is a frequent cause of anaphylac-
tic reactions and death among food allergies and hence 
a severe disease. As peanut is used in a vast number of 
different food products, exposure is largely unpredict-
able. The psychosocial and economic consequences are 
therefore of major importance [3]. Peanuts contain up 
to 30% of allergenic proteins [4], there are at least 16 al-
lergens described (Ara h nomenclature) [5]. As immu-
notherapy (SIT) is typically thought to be allergen-spe-
cific, the preferred therapeutic concept is the use of al-
lergen extracts for SIT to target all possible allergens. 
Efficacy and safety of this approach may be enhanced by 
using allergoids [6] or displaying allergens on virus-like 
particles [7] and optimizing the use of adjuvants [8]. 
Nevertheless, the use and standardization of allergen 
extracts is complex and immunogenicity/efficacy re-
mains limited. While the exact mechanism of how SIT 
reduces allergic symptoms is still under debate, it has 
recently been shown that monoclonal antibodies 
(mAbs) against Fel d 1, the major and essentially only 
clinically relevant allergen in cats, can dramatically im-
prove symptoms of allergy in mice [9] and humans [10]. 
However, it remains unclear whether targeting complex 
allergen mixtures by mAbs is also a feasible therapeutic 
approach.
Materials and Methods
Production of Peanut Extract and Ara h 2
The production of roasted peanut extract and Ara h 2 including 
the protein characterization on SDS-Page are described in Storni 
et al. [J Allergy Clin Immunol, 2020, in press].
Generation of CuMVtt-Ara h 2 and Ara h 2 Specific Antibodies
Mice were immunized with recombinant Ara h 2 coupled to 
virus-like particles derived from cucumber mosaic virus [Storni et 
al., J Allergy Clin Immunol, 2020, in press]. WT BALB/c mice were 
immunized four times with CuMVtt-Ara h 2 (twice s.c. and twice 
i.v., with an interval of 2 weeks) and mAb was generated according 
to standard protocols [11].
ELISA for Determining the Isotype Subclass of mAbs Anti-Ara 
h 2 and Binding to Ara h 2, Peanut Extract, Ara h 1, and Ara 
h 6
96-well Nunc MaxisorpTM ELISA plates (Thermo Fisher Scien-
tific, Waltham, MA, USA) were coated with 1 µg/mL Ara h 2 in 
carbonate buffer at 4  ° C overnight. After blocking with PBS/0.15% 
casein solution for 2 h, plates were washed five times with 
PBS/0.05% Tween. Serial dilutions of mAbs anti-Ara h 2 were add-
ed to the plates and incubated for 2 h at 4  ° C. Plates were then 
washed five times with PBS/0.05% Tween. For determination of 
peanut extract specific IgG subclasses, biotin-labeled mouse anti-
mouse IgG1 (The Jackson Laboratory, Bar Harbor, ME, USA), bi-
otin-labeled mouse anti-mouse IgG2a (Becton Dickinson, Frank-
lin Lakes, NJ, USA), or biotin-labeled rat anti-mouse IgG2b (Bio-
Legend, San Diego, CA, USA) were used as detection antibodies 
for 1 h at 4  ° C. Thereafter, HRP-labeled streptavidin (DakoCyto-
mation, Denmark) was incubated at 4  ° C for 1 h. To determine the 
binding or cross-reactivity of anti-Ara h 2 IgG to peanut extract, 
Ara h 2, Ara h 1, or Ara h 6, ELISA plates were coated with the cor-
responding antigen in a concentration of 2 µg/mL in carbonate 
buffer at 4  ° C overnight. Serial dilutions of IgG anti-Ara h 2 were 
added to the plates and incubated for 2 h at 4  ° C. Plates were then 
washed five times with PBS/0.05% Tween. Thereafter, HRP-la-
beled goat anti-mouse IgG (The Jackson Laboratory, Bar Harbor, 
ME, USA) antibodies were incubated at 4  ° C for 1 h. ELISAs were 
developed with TMB (3,30,5,50-tetramethyl-benzidine) and H2O2 
and stopped with 1 mol/L sulfuric acid. Optical densities were 
measured at 450 nm.
Dot Blot to Determine Binding of Anti-Ara h 2 IgG to 
Recombinant Ara h 2 and Peanut Extract
To confirm binding of anti-Ara h 2 IgG to Ara h 2 and peanut 
extract, serial dilutions of Ara h 2 or peanut extract were applied 
on a nitrocellulose membrane. The membrane was boiled for 5 
min at 900 W in a 4.3 mM Na2HPO4 1.4 mM KH2PO4 containing 
buffer to expose epitopes and increase antigen binding. Thereafter, 
the membrane was washed twice with PBS/0.05% Tween and once 
in PBS and blocked in a 50 mM Tris-buffer containing 0.1% 
Tween20 and 2.5% casein for 1 h at room temperature. The mem-
brane was further incubated with anti-Ara h 2 IgG 10 µg/mL for 2 
h at room temperature. After washing, the membrane was incu-
bated with goat anti-mouse IgG conjugated with horse-radish per-
oxidase (Jackson ImmunoResearch Laboratories, USA) for 1 h at 
room temperature. The membrane was developed with Thermo 
ScientificTM SuperSignalTM West Femto (Thermo Fisher Scientific, 
Waltham, MA, USA) and pictures were acquired with an Azure 
C300 Imaging System (Axon Lab AG, Switzerland).
Binding of mAb Anti-Ara h 2 to FcγRIIb and Generation of 
Biosensor
Biosensor Apparatus
The electrochemical measurements were performed with a 
Metrohm Autolab, PGSTAT320N, potentiostat/galvanostat, con-
trolled by NOVA 1.11 software. The carbon screen printed elec-
trodes (carbon-SPEs) were of commercial origin (Orion, Madrid, 
Spain) – any other carbon-SPEs may be applied herein. The three-
electrode system of the carbon-SPEs contained (i) a counter elec-
trode made of carbon, (ii) a reference electrode made of silver, and 
(iii) a carbon working electrode of 4 mm diameter. All electrical 
connections were made of silver. The carbon-SPEs were inter-
faced with the potentiostat by means of a switch box (BioTID, 
Portugal).
Synthesis of the Sensing Layer
The system used to build this biosensor is similar to the one 
previously described [12]. Following the previous biosensor delin-
eation, we applied FcγRIIb probes to make a bio-interface with 
carbon-SPEs (from Orion). Antibody and immune complex bind-
ing was made by casting standard solutions of mAb anti-Ara h 2 
or mixed equimolarly with Ara h 2. Each standard was incubated 
for 30 min at 37  ° C. The positive serum samples were tested simi-
larly using anti-FcγRIIb antibodies.
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Electrochemical Procedures
The electrochemical studies of electrochemical impedance 
spectroscopy (EIS) were performed in the iron redox probe solu-
tion as described [12]. To analyze EIS data, Nyquist plots were used 
to plot the obtained spectra, showing the frequency response of the 
electrolyte system and plotting the imaginary component (Z″) of 
the impedance against its real component (Z′). EIS data was fitted 
herein into the typical Randle’s equivalent circuit, which matched 
the physiochemical processes occurring at the carbon electrode 
surface [12].
Mice Challenge Experiments
Female WT BALB/c mice (Envigo, Huntingdon, UK) were 
purchased at the age of 6 weeks and kept at the DBMR animal fa-
cility, Murtenstrasse 31, Bern. All animals were used for experi-
mentation according to protocols approved by the Swiss Federal 
Veterinary Office (license BE 70/18).
Seven- to eight-week-old naïve BALB/c mice were sensitized to 
peanut by injecting i.p. at day 0 and day 7 with 5 µg roasted peanut 
extract mixed in 200 µL alum (10 mg/mL Al(OH)3; Alhydrogel; 
InvivoGen, USA).
For the induction of anaphylaxis, sensitized mice were chal-
lenged i.v. with 20 µg roasted peanut extract in 200 µL PBS 2 weeks 
after sensitization. Temperature was measured with a rectal probe 
thermometer (Vetronic Services LTD, Devon, UK) before i.v. an-
tigen challenge and monitored for 50 min after challenge every 10 
min.
The local anaphylaxis was assessed by ear prick test. Mice were 
injected i.v. with 200 µL of Evans blue solution (0.5% in PBS). Af-
terwards, a drop of peanut extract solution (180 µg/20 µL PBS) was 
placed onto the outer ear skin of anesthetized mice. Pricks on the 
ear skin were performed with 23-G (0.6 mm Å∼25 mm) needles 
(Microlance, BD, USA). To assess FcγRIIb receptor function, de-
signed ankyrin repeat proteins (DARPins, described in Zellweger 
et al. [13]) against mouse FcγRIIb receptor were used for blocking 
the receptor by means of local subcutaneous injection on the ears 
10 min before the ear prick. Dye extravasations started immedi-
ately after antigen challenge. Forty minutes later, mice were sacri-
ficed and ears were collected and imaged with an Azure C300 Im-
aging System (Axon Lab AG, Switzerland). Surface of the blue ex-
travasation was quantified by Fiji Image J software.
To investigate the effect of anti-Ara h 2 IgG, 200 µg of mAbs 
were injected i.v. in 200 µL PBS 24 h before challenge with the 
whole peanut extract. Control mice were injected with 200 µg of 
murine monoclonal anti-Fel d 1 IgG. Challenge was performed i.v. 
or via skin prick test.
To assess FcγRIIb receptor function, designed ankyrin repeat 
proteins (DARPins) [13] against mouse FcγRIIb receptor were 
used for blocking the receptor by means of local subcutaneous in-
jection on the ears 10 min before the ear prick. To assess the role 
of the inhibitory FcγRIIb receptor on basophils and mast cells on 
a systemic level, mice were injected i.v. with 150 µg anti-FcγRIIb 
antibody (AT128) 24 h before i.v. challenge with peanut extract. 
As a control isotype antibody, 150 µg anti-histidine antibodies 
were injected in control mice.
Statistical Analysis
Statistical tests were performed with GraphPad PRISM 6.0 
(Graph-Pad Software, Inc., La Jolla, CA, USA). Statistical signifi-
cance is displayed as p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), 
p ≤ 0.0001 (****). Groups for dot surface after skin prick test were 
analyzed by unpaired two-tailed Student’s t test. Anaphylaxis 
curves were analyzed by repeated measures two-way ANOVA test.
Results
Monoclonal IgG Anti-Ara h 2 Binds to Recombinant 
Ara h 2 and Peanut Extract
The monoclonal IgG anti-Ara h 2 was generated ac-
cording to standard procedures upon immunization of 
mice with Ara h 2 coupled to CuMVtt [Storni et al., J Al-
lergy Clin Immunol, 2020, in press]. As shown in Figure 
1a, the antibody isotype is IgG2a, while the antibody has 
specificity for Ara h 2 and peanut extract as demonstrated 
by ELISA (Fig. 1b) and dot blot (Fig. 1c). Cross-reactivity 
of this mAb to Ara h 1 and Ara h 6 was low. Therefore, 
we attribute the main effect of mAb anti-Ara h 2 in vivo 
described below to Ara h 2 specificity and not to cross-
reactivity to other peanut allergens.
mAb Anti-Ara h 2 Binds to Murine FcγRIIb
Affinities of IgG antibodies to the FcγRIIb are low in 
general even if immune-complexed to allergen and these 
interactions are therefore very hard to measure. To be 
able to measure specific interaction between FcγRIIb and 
mAb anti-Ara h 2, we employed a highly sensitive biosen-
sor previously described for measurement of antibodies 
directed against Plasmodium falciparum and Zika virus 
[12]. To this end, recombinant murine FcγRIIb was coat-
ed on a carbon-SPE before incubation with mAb anti-Ara 
h 2 in free form or immune-complexed with Ara h 2.
We have previously shown that binding of ligands to 
carbon-nanotube bound protein changes the electric 
properties, causing changes in electrical impedance, 
which was used as a read-out for protein binding as de-
scribed earlier [14, 15]. As shown in Figure 2a and b, mAb 
anti-Ara h 2 bound in free and in immune-complexed 
form to recombinant FcγRIIb. However, the binding of 
immune-complexed anti-Ara h 2 to FcγRIIb was stronger 
than to free anti-Ara h 2, in line with previous findings 
showing that immune complexes bind FcγRIIb more ef-
fectively than free mAb.
IgG Anti-Ara h 2 Protects against Anaphylaxis
To investigate the protective potential of IgG anti-Ara 
h 2 against anaphylaxis, sensitized BALB/c mice were in-
jected i.v. with mAbs anti-Ara h 2 24 h before i.v. or skin 
prick challenge. Injection of 200 µg mAbs anti-Ara h 2 
into peanut-sensitized mice protected from anaphylactic 
reactions (Fig. 3a).
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IgG Anti-Ara h 2 Diminishes Local Reaction after 
Challenge via Skin Prick Test
To examine the effect of IgG anti-Ara h 2 on local al-
lergic reactions, skin prick tests were performed in pea-
nut-sensitized mice injected with mAbs or monoclonal 
anti-Fel d 1 antibody, as control. In order to visualize ex-
travasation, mice were pretreated i.v. with Evans blue 
[11]. Allergen challenge by pricking into the ear skin with 
peanut extract induced vascular leakage in control mice. 
In contrast, animals pretreated with IgG anti-Ara h 2 
showed significantly smaller extravasation surface 
(Fig. 3b).
The Inhibitory FcγRIIb Receptor Is Required for 
Protection Induced by Anti-Ara h 2 IgG
To investigate whether the inhibitory FcγRIIb recep-
tor present on mast cells and basophils is involved in the 
protection induced by IgG antibodies generated after an-
ti-Ara h 2 injection, peanut-sensitized BALB/c mice were 
challenged i.v. 24 h after injection of an anti-FcγRIIb 
mAb (AT 128) to block the FcγRIIb receptor or a control 
murine IgG. As shown in Figure 3c, the protection con-
ferred by passive vaccination with mAbs IgG anti-Ara h 
2 was abrogated by systemic injection of FcγRIIb-blocking 
antibody. Protection was not affected when mice were in-
jected with isotype control IgG.
The involvement of the inhibitory receptor FcγRIIb in 
protection was confirmed via skin prick test after locally 
blocking the FcγRIIb receptor with an inhibitor molecule 
(based on DARPin technology) specific to FcγRIIb [16]. 
As shown above, anti-Ara h 2 IgG-treated mice developed 
much smaller extravasation spots after ear skin prick test, 
but protection was abrogated by local co-injection of 
FcγRIIb-blocking DARPin. Mice with blocked FcγRIIb 
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showed a comparable leakage to allergen-challenged mice 
without prior exposure to mAbs, demonstrating that in-
hibitory receptor FcγRIIb is required for protection 
(Fig. 3b).
Discussion/Conclusion
The goal of immunotherapy in allergic patients is to 
induce tolerance or reduced responsiveness to the aller-
gen. Efficacy of oral immunotherapy in peanut-allergic 
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patients was demonstrated in a phase 3 clinical trial for 
children and adolescents [17]. In recent studies, induc-
tion of regulatory T cells [18] or a shift from Th2 to Th1 
[19] were discussed as possible mechanisms underlying 
induction of tolerance. The central role of allergen-spe-
cific IgGs in allergy protection was recently strikingly 
demonstrated in a clinical study with anti-Feld d 1 mAbs 
[10]. Here we extend these findings from a single aller-
gen-disease (sensitization to Fel d 1) to complex allergen 
mixtures and demonstrate in mice that targeting the sin-
gle major allergen Ara h 2 in a complex allergen mixture 
is sufficient to control disease symptoms upon local and 
systemic allergen challenge. This finding is consistent 
with previous studies demonstrating successful immuno-
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therapy based on one allergen in polysensitized patients 
[20]. The present experiments extend these findings to 
show that a single mAb specific for a single allergen may 
be able to cause similar protection. Our study may pres-
ent a limitation concerning the animal model (intraperi-
toneal way of sensitization and intravenous allergen chal-
lenge, both not physiologic for peanut allergy in humans). 
Nevertheless, parenteral allergen injection may repro-
duce a systemic allergen exposure as previously shown 
[21]. Further studies including experiments with differ-
ent mAbs presenting distinct specificities are needed to 
support this novel concept. Potential clinical applications 
of protective mAbs against allergy are imaginable espe-
cially in prophylactic settings in severely allergic patients 
at risk for anaphylactic shock.
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